Vivos Therapeutics, Inc. Interest Expense
Vivos Therapeutics, Inc. (VVOS) reported Interest Expense of $1.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-14
- Vivos Therapeutics, Inc. interest expense for the quarter ending 2026-06-30 was $1.10M.
- Vivos Therapeutics, Inc. interest expense for the quarter ending 2026-03-31 was $1.10M.
- Vivos Therapeutics, Inc. interest expense for the quarter ending 2025-12-31 was $800.00K.
- Vivos Therapeutics, Inc. interest expense for the quarter ending 2025-09-30 was $500.00K.
- Vivos Therapeutics, Inc. interest expense for fiscal 2025 was $1.40M.
- Vivos Therapeutics, Inc. interest expense for fiscal 2021 was $14.00K, a 85.42% decline from fiscal 2020.
- Vivos Therapeutics, Inc. interest expense for fiscal 2020 was $96.00K, a 30.37% decline from fiscal 2019.
- Vivos Therapeutics, Inc. interest expense for fiscal 2019 was $137.88K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-14 | $2.20M 10-Q · filed 2026-08-14 | $3.00M derived: sum of 3 quarters · filed 2026-08-14 | $3.50M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-20 | $1.90M derived: sum of 2 quarters · filed 2026-05-20 | $2.40M derived: sum of 3 quarters · filed 2026-05-20 | ||
| 2025-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $1.30M derived: sum of 2 quarters · filed 2026-04-15 | $1.40M 10-K · filed 2026-04-15 | ||
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-19 | $600.00K 10-Q · filed 2025-11-19 | |||
| 2021-12-31 | $4.18K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $13.67K derived: sum of 2 quarters · filed 2023-03-30 | $13.92K derived: sum of 3 quarters · filed 2023-03-30 | $14.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $9.49K 10-Q · filed 2021-11-15 | $9.74K derived: sum of 2 quarters · filed 2021-11-15 | $9.82K 10-Q · filed 2021-11-15 | $27.04K derived: sum of 4 quarters · filed 2022-03-31 | |
| 2021-06-30 | $251.00 10-Q · filed 2021-08-12 | $333.00 10-Q · filed 2021-08-12 | $17.55K derived: sum of 3 quarters · filed 2022-03-31 | $34.54K derived: sum of 4 quarters · filed 2022-03-31 | |
| 2021-03-31 | $82.00 10-Q · filed 2021-05-17 | $17.30K derived: sum of 2 quarters · filed 2022-03-31 | $34.29K derived: sum of 3 quarters · filed 2022-03-31 | $52.36K derived: sum of 4 quarters · filed 2022-03-31 | |
| 2020-12-31 | $17.22K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $34.21K derived: sum of 2 quarters · filed 2022-03-31 | $52.28K derived: sum of 3 quarters · filed 2022-03-31 | $96.00K 10-K · filed 2022-03-31 | $96.68K 10-K · filed 2021-03-25 |
| 2020-09-30 | $16.99K 10-Q · filed 2021-11-15 | $35.06K derived: sum of 2 quarters · filed 2021-11-15 | $78.78K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $18.07K 10-Q · filed 2021-08-12 | $61.79K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $43.72K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $137.88K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |